Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis

Wei Wang, Caiyan Zhao*, Junying Zhou, Zhen Zhen, Yadong Wang, Chuan Shen

Department of Infectious Diseases, the Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China

Abstract

Background: Simvastatin exerts pleiotropic effects on cardiovascular system. However, its effect on non-alcoholic fatty liver disease, especially the liver fibrosis, remains obscure. We aimed to clarify the relationship between simvastatin and liver fibrosis both in vivo and in vitro.

Methods: A High-fat diet was given to establish rat models with non-alcoholic steatohepatitis (NASH)-related liver fibrosis and simvastatin (4mg·kg⁻¹·d⁻¹) was administrated intragastrically until hepatic histological findings confirmed the appearance of fibrosis. Human hepatic stellate cell (HSC) line lx-2 cells were cultured in an adipogenic differentiating mixture (ADM) and then were treated with transforming growth factor β1 (TGF-β1), served as a positive control, simvastatin, TGF-β1 plus simvastatin, \( N_\omega -\text{nitro-L-arginine methyl ester hydrochloride} \) (L-NAME, a inhibitor of nitric oxide synthase), and L-NAME plus simvastatin, respectively. The expressions of endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), and Collagen І as well as cellular α-smooth muscle actin (α-SMA) were measured by real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) and Western blot in liver tissue and HSC.

Results: With the progress of NASH-related fibrosis, hepatic mRNA and protein expressions of iNOS, α-SMA, and Collagen І were increased while those of eNOS were decreased. Compared with model rats in 24th week group, rats in simvastatin group had less expressions of iNOS, α-SMA, and Collagen І and more expressions of eNOS. In vitro, LX-2 cells acquired quiescent phenotype when cultured in ADM, and TGF-β1 could activate the quiescent HSC. Simvastatin inhibited LX-2 cells activation due to TGF-β1 or L-NAME by increasing the expression of eNOS and decreasing the expression of iNOS.

Conclusions: Simvastatin improves the prognosis of NASH-related fibrosis by increasing the expression of eNOS, decreasing the expression of iNOS, and inhibiting the activation of HSC.

Citation: Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, et al. (2013) Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis. PLoS ONE 8(10): e76538. doi:10.1371/journal.pone.0076538

Editor: Carlos M Rodriguez-Ortigosa, CIMA. University of Navarra, Spain

Received March 26, 2013; Accepted August 28, 2013; Published October 2, 2013

Copyright: © 2013 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by a grant from the Ministry of Education in Hebei Province as a major project of science and technology, number ZD2010225. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: zhaocy2005@163.com

Introduction

Non-alcoholic fatty liver disease (NAFLD) has become a growing public health concern and been considered to be the most common cause of chronic liver disease in Western countries [1-4]. In China, it is increasingly diagnosed as well. NAFLD involves a histopathological spectrum ranging from benign simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even malignant hepatocellular carcinoma [5-11]. The profibrogenic mechanisms operating in NASH are complicated, and insulin resistance, oxidative stress, altered cytokines, especially adipokines, might play important roles in the fibrogenesis in NASH-related fibrosis [7,8]. Many studies have reported that transforming growth factor β1 (TGF-β1) is increased in serum and hepatic tissues in the NAFLD patients and animal models [12,13]. It can promote hepatic fibrogenesis by activating hepatic stellate cells (HSC) in both autocrine and paracrine way. HSC is recognized as the major source of extracellular matrix (ECM), of which increased or altered deposition can lead to fibrosis and severe cirrhosis.

Recently, statins have been considered to exert pleiotropic effects on cardiovascular system [14]. Researchers found that statins, such as pitavastatin, atorvastatin, and rosuvastatin, could improve the activity of NAFLD by ameliorating the
hepatic steatosis, hepatitis, and fibrosis [15-17]. Simvastatin was also reported to lower the elevated liver enzymes and reduce hepatic fatty infiltration in patients with NAFLD [18], and to stabilize or reverse fibrosis [19] by inhibiting HSC proliferation [20]. However, many other studies obtained the negative outcomes or the converse results. Therefore, it is still controversial that whether simvastatin has the therapeutic effect on NAFLD, particularly on NASH-related hepatic fibrosis.

Nitric oxide (NO) is generated constitutively from sinusoidal endothelial cells mediated by endothelial NO synthase (eNOS) under normal physiological conditions [21]. eNOS-derived NO exerts paracrine effects on adjacent HSC, inhibiting the vasoconstriction, proliferation, and migration. During the inflammation, inducible NO synthase (iNOS) plays a major role in NO production contributing to tissue damage [22]. Simvastatin has been concerned to increase eNOS activity, enhance NO bioavailability, and prevent a significant increase in iNOS in rats after ischemia-reperfusion [23]. In addition, HSC has the ability to excrete a little content of eNOS in normal condition. Therefore, we presume that simvastatin might inhibit the activation of HSC by increasing eNOS expression and decreasing iNOS expression.

In this study, we aim to demonstrate whether simvastatin exert an antifibrogenic effect on rats with NASH-related hepatic fibrosis and how it works.

Materials and Methods

Reagents
3-Isobutyl-1-methylxanthine, dexamethasone, insulin, Dulbecco’s modified Eagle’s medium (DMEM), Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME), simvastatin were purchased from Sigma-Aldrich (Saint Louis, MO, USA), fetal bovine serum (FBS) was purchased from Gibco (Langley, OK, USA), recombinant human transforming growth factor β1 (TGF-β1) was obtained from Peprotech (Rocky hill, NJ, USA), Trizol reagent was obtained from Invitrogen (Carlsbad, CA, USA), reverse transcription system and oligonucleotide primers were obtained from Promega (Madison, WI, USA), iTaq SYBR Green supermix used for PCR were purchased from Bio-Rad (Hercules, CA, USA), antibodies against eNOS, iNOS, α-smooth muscle actin (α-SMA), Collagen I, and β-actin, and secondary antibodies were all purchased from Santa Cruz (Santa Cruz, CA, USA).

Rat models with NASH-related hepatic fibrosis
Forty-eight male Wistar rats weighting from 140 grams to 160 grams were approved from the experimental animal center of Hebei medical university. The animals were maintained on a controlled temperature (20°C-24°C) and humidity (65%-75%), and they had free access to food and water. After one week of acclimatization, all the 48 rats were divided randomly into two groups, the control group fed with standard diet and the model group fed with high-fat diet (standard diet plus 10% lard, 2% cholesterol, and 5% corn oil). There were 12 rats in the control group and 36 in the model group. Of 36 rats with high-fat diet, six rats were respectively sacrificed at the ends of 8th, 12th, 16th week by bloodletting at femoral vein. Hepatic histological examinations confirmed that liver fibrosis appeared at the end of 16th week. Since then, six rats were separated randomly from the rest of 18 rats in the model group and started to treat with simvastatin intragastrically besides the high-fat diet. At the ends of 20th week, six rats were sacrificed randomly in the model group. And at the ends of 24th week, the rest six rats with high-fat diet and six rats with simvastatin plus high-fat diet were all sacrificed. Of 12 rats in the control group, two were sacrificed respectively at the end of 8th, 12th, 16th, 20th week, and four were sacrificed at the end of 24th week. The sera were collected to examine the serum biochemical markers, and liver specimens were obtained to observe hepatic pathological changes and to detect the hepatic mRNA and proteins.

All animal protocols and practices were reviewed and approved by the Hebei Medical University Experimental Animal Center. All rats were anesthetized with 1% sodium pentobarbital given i.p. before sacrificed by bloodletting at femoral vein, and they received humane cares indeed which minimize animal pain or discomfort.

Cell culture
Human HSC line LX-2 cells from the cell bank of Chinese Academy of Sciences were cultured in DMEM containing 10% FBS, penicillin (100 U/ml), and streptomycin (100 µg/ml) at 37°C with 5% CO2. Cells were seeded in six well plates at a density of 5 × 10^5 cells per well until 70% cells confluent, and then treated with the adipogenic differentiation mixture (ADM), which containing 0.5 mM 3-Isobutyl-1-methylxanthine, 1 µM dexamethazone, and 1 µM insulin. Seventy-two hours later, ADM was changed to DMEM with 0.2% FBS, penicillin, and streptomycin for 24 hours to achieve cell synchronization. After that, cells were respectively treated with solvent (the control group), TGF-β1 (100 pM, the positive control group), simvastatin (10 µM), TGF-β1 plus simvastatin, L-NAME (100 µM), and L-NAME plus simvastatin for 24 hours, and were harvested to assess the expressions of eNOS, iNOS, α-SMA, and Collagen I.

Biochemical assay
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol (TC), and triglyceride (TG) of rats were measured using an auto-biochemical analyzer OLYMPUS AU-600 from Olympus Corporation (Shinjuku, Japan).

Staining
Some of liver specimens were made of frozen sections and were stained by Sudan IV for hepatic steatosis. Another part was fixed with 10% formalin and then was made of paraffin sections. Hematoxylin-eosin (HE) staining was used for observing the general hepatic pathological changes, particularly hepatocellular ballooning degeneration, inflammatory cells infiltration, and necrosis, and Masson staining for fibrosis.
Quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis

Total RNA of liver tissue and LX-2 cells were separately extracted by Trizol reagent, quantified by spectrophotometry, reverse-transcribed to cDNA by reverse transcription system, and amplified by PCR mix with specific oligonucleotide primers for target sequences and β-actin, which served as internal control. The primers of hepatic markers were: eNOS forward 5'-TGACCTCAGCATAACAA-3', reverse 5'-CTGGCCTTCTGCTATAAA-3'; α-SMA forward 5'-TGCCATTGTTGGTGGAGTAA -3'; β-actin forward 5'-AGCACTGTGTTGGCGTACAG-3'. Threshold cycles (Ct) values of target genes were calculated and normalized to that of β-actin.

Western blot analysis

Total protein of liver tissue and LX-2 cells were extracted and quantified respectively. After sodium dodecyl sulfate-PAGE, the protein was transferred from gel to Polyvinylidene fluoride membrane by semi-dry transfer method. The membrane was blocked and incubated with antibodies against eNOS, iNOS, α-SMA, Collagen I, and β-actin overnight at 4°C. Then membrane was incubated with secondary antibodies and the protein was detected with enhanced chemiluminescence kit. Bio-Profil system was used to analyze the relative quantization of target protein.

Statistical analysis

The results were expressed as the mean ± standard deviation and were analyzed using one-way ANOVA or Student-Newman-Keuls test. A P value of less than 0.05 was considered as statistically significant.

Results

Simvastatin decreased the levels of serum ALT, AST, TC, and TG

The levels of serum ALT, AST, TC, and TG were all increased with the consumption of high-fat diet. Compared with rats in the 24th week group, the levels of ALT, AST, TC, and TG were all declined in rats of simvastatin-treatment group (P<0.05) (Table 1).

Simvastatin improved the hepatic pathological changes

With the consumption of high-fat diet, hepatic steatosis, inflammation, and fibrosis were all aggravated. Hepatic histopathological observation revealed that steatosis appeared at the end of 8th week, steatohepatitis established at the end of 16th week (Figures 1 and 2). Hepatocellular ballooning degeneration, inflammatory cells infiltration, spotty focal necrosis, moderate or severe hepatocellular steatosis were shown in the hepatic lobule, especially in zone 3 of acinus (Figures 1 and 2). At 16th week, part of model rats showed slightly fibrosis in sinusoids. At 24th week, all model rats exhibited sinusoidal fibrosis (Figure 3). These conditions were improved in rats of simvastatin-treatment group (Figures 1D, 2D, and 3D).

Simvastatin increased the hepatic expression of eNOS and decreased the hepatic expression of iNOS and Collagen I both in mRNA and protein levels

With the progress of NASH, hepatic expression of eNOS both in mRNA and protein levels in model rats were gradually decreased compared with that in the control group (P<0.05), while the expression of iNOS and Collagen I were gradually increased (P<0.05). Compared with rats only fed with high-fat diet for 24 weeks, rats treated with simvastatin had higher mRNA expression of eNOS (1.30 folds, P<0.05) and Collagen I (0.72 fold, P<0.05) and Collagen I (0.58 fold, P<0.05) expressions were lower. The changes of protein expressions were consistent with that of genes (P<0.05) (Figure 4).

Simvastatin inhibited the activation of quiescent LX-2 cells, increased the cellular expression of eNOS and decrease the cellular expression of iNOS both in mRNA and protein levels

It had been reported that ADM could convert active HSC into quiescent phenotype [24], which was also confirmed by our former studies [25]. In this study, LX-2 cells approximately acquired quiescent phenotypes by culturing with ADM for three days. These cells were used for investigating the molecular mechanism of HSC activation.

TGF-β1 plays a critical role in the initiation, promotion, and progression of HSC activation and contributes to increased

### Table 1. Serum biological examinations in each group of rats.

| Group | n | ALT (U/L) | AST (U/L) | TC (mmol/L) | TG (mmol/L) |
|-------|---|-----------|-----------|-------------|-------------|
| Control | 12 | 45.30±11.35 | 71.80±9.46 | 1.81±0.20 | 0.41±0.10 |
| 8th week | 6 | 65.00±10.39 | 93.17±14.27 | 2.77±0.31 | 0.69±0.12 |
| 12th week | 6 | 105.50±13.74 | 128.67±14.92 | 3.45±0.32 | 0.86±0.10 |
| 16th week | 6 | 120.50±11.06 | 149.50±9.20 | 3.85±0.19 | 1.02±0.13 |
| 20th week | 6 | 138.67±9.63 | 178.00±8.07 | 4.15±0.23 | 1.24±0.18 |
| 24th week | 6 | 163.00±17.34 | 193.00±8.85 | 4.51±0.21 | 1.41±0.08 |
| Simvastatin | 6 | 132.67±0.09 | 152.50±13.32 | 4.20±0.23 | 1.25±0.10 |

F value | 9.92 |
| P value | <0.01 |

* P<0.05, compared with the control group; **P<0.05, compared with 24th week group.

Plosone www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e76538
synthesis of myofibroblast phenotype marker gene α-SMA and ECM components such as Collagen І. Therefore, TGF-β1 was selected as a positive control in our study to explore whether simvastatin could inhibit HSC activation. The results showed that α-SMA and Collagen І mRNA and protein expression of quiescent LX-2 cells treated with TGF-β1 were 3 folds higher than that of the control (all $P<0.05$). And compared with the TGF-β1 group, simvastatin could reduce the expression of α-SMA and Collagen І (all $P<0.05$).

Compared with the control group, simvastatin-treated quiescent LX-2 cells had higher eNOS mRNA and protein expressions (1.29 folds and 1.16 folds, respectively, $P<0.05$), lower iNOS expression (0.61 folds and 0.35 folds, respectively, $P<0.05$), and similar α-SMA and Collagen І expressions, with no significant differences (Figure 5).

Furthermore, simvastatin inhibited the activation of LX-2 cells induced by TGF-β1. Compared with the TGF-β1 group, simvastatin plus TGF-β1 group expressed less α-SMA (0.79 folds and 0.86 folds, respectively, $P<0.05$), Collagen І (0.79 folds and 0.82 folds, respectively, $P<0.05$), and iNOS (0.30 folds and 0.45 folds, respectively, $P<0.05$), and more eNOS (2.18 folds and 1.73 folds, respectively, $P<0.05$), both in mRNA and protein levels.

Simvastatin antagonized the decreased expression of eNOS mediated by L-NAME

L-NAME serves as a competitive inhibitor of NOS, especially selective inhibitor of the constitutive isoforms, which mainly refer to eNOS in the liver tissue. In our study, L-NAME was used to inhibit the expression of eNOS and to demonstrate the important role of eNOS in the mechanism of NASH-related fibrosis both in vivo and in vitro. Compared with the control cells, L-NAME treated quiescent LX-2 cells had higher mRNA expressions than the control group (all $P<0.05$). This experiment confirmed that simvastatin could inhibit the activation of LX-2 cells, and the expression of α-SMA and Collagen І were downregulated, with the expression of eNOS upregulated (Figure 5).

**Figure 1.** Hematoxylin-eosin staining of hepatic tissues in each group of rats. With the consumption of high-fat diet, hepatocellular steatosis, ballooning degeneration, lobular inflammation, spotty focal necrosis were gradually shown in the hepatic lobule, especially in zone 3 of acinus. At the end of 8th week, simple steatosis appeared with no inflammatory cell infiltration. At the end of 16th week, steatohepatitis established with inflammatory cell infiltration and spotty focal necrosis (B). At the end of 24th week, numerous polymorphs and mononuclear cells infiltration and portal inflammation were frequently observed (C). These changes were improved in the liver of simvastatin-treated rats (D). A: Control ×200; B: 16th week ×200; C: 24th week ×200; D: Simvastatin-treated group ×200.

doi: 10.1371/journal.pone.0076538.g001
and protein expressions of α-SMA (3.46 folds; 3.00 folds, $P<0.05$) and Collagen I (3.53 folds; 3.10 folds, $P<0.05$), and lower eNOS (0.27 fold; 0.27 fold, $P<0.05$) and iNOS expressions (0.60 fold; 0.40 fold, $P<0.05$), which were mostly similar to that of TGF-β1 group (a positive control), except iNOS expression.

Simvastatin could reverse these changes caused by L-NAME in both mRNA and protein levels. Compared with the L-NAME group, simvastatin plus L-NAME could decrease the expression of α-SMA (0.75 fold and 0.72 fold, respectively, $P<0.05$) and Collagen I (0.77 fold and 0.84 fold, respectively, $P<0.05$), increase the expression of eNOS (2.44 folds and 1.92 folds, respectively, $P<0.05$) (Figure 6).

Discussion

NAFLD is a complex disorder and is recognized as the hepatic manifestation of metabolic syndrome and insulin resistance [26,27]. It is considered as a progressive liver disease which has the potential to progress to cirrhosis and hepatocellular carcinoma (HCC). Recent studies demonstrated that NASH may be a leading cause of cryptogenic cirrhosis, so effective therapies are needed to ameliorate hepatic steatosis, inflammation, and fibrosis, and to prevent the progression to cirrhosis and HCC. In addition, patients with NAFLD and NASH are at increased risk for cardiovascular disease and dyslipidemia treatments should be offered to reduce the cardiovascular risk. Therefore, statins are thought to be available to the management of NAFLD [28].

Simvastatin is one of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors which have lipid-lowering property. In addition, it also exhibits potential benefits such as anti-inflammation, anti-oxidation, improving endothelial dysfunction, increasing nitric oxide bioavailability, stabilizing the atherosclerotic-plaques, decreasing intrahepatic vascular resistance, and reducing portal pressure [29,30]. Therefore, simvastatin may be an optional treatment in patients with NAFLD [31]. Recent studies mostly demonstrated that simvastatin not only reduced circulating low-density lipoprotein cholesterol but decreased hepatic lipid deposition in patients
with NASH. However, it was still controversial whether it improved hepatic inflammation and fibrosis [5,19,32]. Nelson A et al. considered that monotherapy with simvastatin does not seem to be an effective treatment for NASH [5]. In their study, a total of 16 patients were enrolled and only 10 patients received simvastatin therapy. If this study enrolled more patients, the result would be different. Additionally, the objects of this study are different from ours, with patients in the former and rats models in the later. The results may be influenced by different study subjects. Zamin Jr I et al. observed that simvastatin could elevate the levels of ALT and AST [32]. In their study, Wistar rats, the same as ours, were used to establish the NAFLD models. But the diets (MCD diet vs. high-fat diet), the dose of simvastatin (0.5 mg/kg/day vs. 4 mg/kg/day), and the course of treatment (started from beginning with the duration of 90 days vs. started from 16th weeks with the duration of 8 weeks) were all different with our study. Therefore, the results of these two studies could not be compared. In this study, simvastatin treatment could ameliorate the progressive hepatic steatosis, inflammation, and fibrosis induced by high-fat diet, indicating that simvastatin had protective effects on the pathogenesis of NASH. Furthermore, cultured quiescent HSC were used to demonstrate whether simvastatin directly improved the hepatic fibrosis besides the indirect function of reduced lipid deposition. The results showed that simvastatin inhibited the activation of HSC and kept the low cellular expressions of α-SMA and Collagen I, suggesting that simvastatin could directly contribute to improvement of hepatic fibrosis.

Since we proved that simvastatin had anti-fibrosis property, the specific mechanism of fibrotic inhibition is further needed to better understand its efficacy. Some studies observed that silent information regulator 1 (SIRT1) and SIRT1-related microRNA-34a were expressed in endothelial progenitor cells obtained from patients with coronary artery disease, and microRNA-34a level was higher than that in non-coronary artery disease subjects. Atorvastatin could contribute to the beneficial effects on endothelial function by up-regulating SIRT1 expression via inhibiting microRNA-34a expression [33]. Another study demonstrated that SIRT1/FoxO3a binding was

Figure 3. Masson staining of hepatic tissues in each group of rats. Slightly sinusoidal fibrosis appeared only in part of model rats until 16th week (B). At the end of 24th week, all model rats showed hepatic fibrosis in sinusoids, partly in portal area (C). These changes were improved in the liver of simvastatin-treated rats (D). A: Control ×200; B: 16th week ×200; C: 24th week ×200; D: Simvastatin-treated group ×200.
doi: 10.1371/journal.pone.0076538.g003
Figure 4. Representative graphs and bar charts of hepatic mRNA and protein expressions of iNOS, eNOS, and Collagen I in each group of rats. The hepatic protein expression of iNOS and eNOS were detected in the control group of rats, with little collagen I expression (A). With the consumption of high-fat diet, the iNOS and collagen I expressions were gradually increased (B, C, F, G), while eNOS expression was gradually decreased (D, E). Compared with rats in the 24th week group, simvastatin treatment could up-regulate eNOS expression (A, D, E) and down-regulate iNOS expression (B, C), followed by improved hepatic fibrosis, which represented by decreased collagen I expression (F, G). (* P<0.05, compared with the control group; † P<0.05, compared with 24th week group.).

doi: 10.1371/journal.pone.0076538.g004
Figure 5. Representative graphs and bar charts of the mRNA and protein expressions of iNOS, eNOS, α-SMA, and Collagen I in LX-2 cells treated with TGF-β1 and simvastatin. Most LX-2 cells obtained the quiescent phenotype after treated with ADM for three days. In LX-2 cells pre-treated with ADM, the mRNA and protein expressions of iNOS and eNOS were detected, with little α-SMA, and Collagen I expressions (A). TGF-β1 behaved as the most powerful activator of HSC and increased the iNOS expression and decreased the eNOS expression (B~E). Compared with the TGF-β1 group of LX-2 cells, LX-2 cells cultured with simvastatin alone or with both simvastatin and TGF-β1 had less iNOS, α-SMA, and Collagen I expressions (B, C, F~I) and more eNOS expression (D, E). (* P<0.05, compared with the control group; * P<0.05, compared with LX-2 cells treated with TGF-β1; ^ P<0.05, compared with LX-2 cells treated with simvastatin.).

doi: 10.1371/journal.pone.0076538.g005
Figure 6. Representative graphs and bar charts of the mRNA and protein expressions of iNOS, eNOS, α-SMA, and Collagen І in LX-2 cells cultured with L-NAME and simvastatin. L-NAME served as a NOS inhibitor; it inhibited both iNOS and eNOS expression (A~E) and induced more α-SMA, and Collagen І expressions (F~I). Simvastatin had antagonistic effect on the activation of LX-2 cells induced by L-NAME via increasing the eNOS expression (D, E). (* P<0.05, compared with the control group; * P<0.05, compared with LX-2 cells treated with L-NAME; ^ P<0.05, compared with LX-2 cells treated with simvastatin.).

doi: 10.1371/journal.pone.0076538.g006
enhanced in rheumatoid arthritis synovial fibroblasts and simvastatin could increase SIRT1 expression, indicating that simvastatin might be beneficial to inflammatory arthritis through its up-regulation of SIRT1/FoxO3a signaling in synovial fibroblasts [34]. In addition, with the progress of NAFLD, microRNA-34a, apoptosis and acetylated p53 were found to be increased gradually in the hepatic tissues, while SIRT1 decreased [35]. Therefore, statins, particularly simvastatin, might play a crucial role in ameliorating the progression of NAFLD, such as hepatic steatosis, inflammation and fibrosis, via regulating microRNA-34a/Sirtuin-1 pathway.

Recent studies have reported that simvastatin decreased hepatic venous pressure gradient and improved liver perfusion in patients with cirrhosis [36]. And simvastatin attenuated pressure response to volume expansion and improved the vascular disturbances contribute to portal hypertension by selectively increased eNOS expression and NO availability in cirrhotic liver [37]. In vitro, simvastatin inhibited the proliferation of HSC and decrease the expressions of collagen I, III, and IV, but the specific mechanism was unclear [20]. So whether this effect is associated with the regulation of NOS needs to elucidate. INOS can be increased by many inflammatory agents. In our study, TGF-β1 could activate the quiescent LX-2 cells by increasing the expression of iNOS and decreasing the expression of eNOS. L-NAME, with a dose of 100 μM, was used to inhibit the expression of both eNOS and iNOS, especially eNOS. And we observed that L-NAME activated microRNA-34a/Sirtuin-1 pathway.

HSC by decreasing the expression of eNOS and iNOS. Therefore, eNOS was considered to play a more important role than iNOS in the mechanism of HSC’s activation. We found that simvastatin increased eNOS expression and decreased iNOS expression both in hepatic tissue and in cultured LX-2 cells. And simvastatin could attenuate L-NAME’s effect on eNOS, increased eNOS expression, and maintained the low level expression of iNOS. Therefore, simvastatin inhibited the activation of quiescent LX-2 cells by regulating the NOS expression.

Conclusions
Simvastatin ameliorates the progression of NASH-related hepatic fibrosis. It decreases the hepatic lipid deposition, attenuates hepatic inflammation, and inhibits the development of fibrosis by inhibiting the activation of HSC via modulating INOS and eNOS. The beneficial effects of simvastatin should be further confirmed in long-term clinical trials for NASH-related fibrosis.

Author Contributions
Conceived and designed the experiments: CZ WW. Performed the experiments: WW. Analyzed the data: WW YY CS. Contributed reagents/materials/analysis tools: JZ ZZ. Wrote the manuscript: WW.

References
1. Younossi ZM (2008) Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28: 2-12. doi:10.1111/j.1365-2036.2008.03710.x. PubMed: 18410557.
2. Lam BP, Younossi ZM (2009) Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 8 Suppl 1: S51-S59. PubMed: 19581125.
3. Vuppalanchi R, Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49: 306-317. doi:10.1002/hep.22603. PubMed: 19066560.
4. Duvnjak M, Lerotić I, Barisć N, Tomasavić V, Viročev Jukić L et al. (2007) Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550. PubMed: 17729403.
5. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 43: 990-994. doi:10.1097/MCG.0b013e1891c392e. PubMed: 19448566.
6. de Alwis NM, Day CP (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 Suppl 1: S104-S112. doi:10.1016/S0168-8278(08)60259-7. PubMed: 18034697.
7. Dowman JK, Tomlinson JW, Newsome PN (2010) Pathogenesis of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 25: 218-226. doi:10.1111/j.1440-1640.2009.05766.x. PubMed: 20034636.
8. Musso G, Gambino R, Cassader M (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26. doi:10.1016/j.plipres.2008.08.001. PubMed: 19162434.
9. Asano T, Watanabe K, Kubota N, Gunji T, Omata M et al. (2009) Adiponectin knockout mice on high fat diet develop fibrosing high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Hepatology Res 41: 375-385. doi:10.1111/j.1872-034X.2010.00769.x. PubMed: 21276150.
10. Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishibori T et al. (2012) Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its turnover necrosis factor-alpha-lowering property. Dig Liver Dis 44: 492-496. doi:10.1016/j.dld.2011.12.013. PubMed: 22265683.
protein synthesis by rat hepatic stellate cells. J Hepatol 38: 564-572. doi:10.1016/S0168-8278(03)80078-9. PubMed: 12713866.

21. Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML et al. (2008) Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol 89: 241-250. doi:10.1111/j.1365-2613.2008.00590.x. PubMed: 18429990.

22. Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W et al. (2009) Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res 39: 963-971. doi:10.1111/j.1872-034X.2009.00539.x. PubMed: 19624767.

23. Trocha M, Merwid-Lad A, Szuba A, Chlebda E, Pieśniewska M et al. (2010) Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivaties (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. Pharmacol Rep 62: 343-351. doi:10.1124/pr.110.002832. PubMed: 20508290.

24. She H, Xiong S, Hazra S, Tsukamoto H (2005) Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 280: 4959-4967. PubMed: 15537655.

25. Zhao C, Chen W, Yang L, Chen L, Stimpson SA et al. (2006) PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350: 385-391. doi:10.1016/j.bbrc.2006.09.069. PubMed: 17010940.

26. Lonardo A, Loria P (2012) If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? Dig Liver Dis 44: 451-452. doi:10.1016/j.dld.2012.02.020. PubMed: 22487461.

27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. doi:10.1002/hep.20701. PubMed: 15915461.

28. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Association. Hepatology 55: 2005-2023. doi:10.1002/hep.25874.

29. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE (2009) Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 150: 5262-5272. doi:10.1210/en.2009-0603. PubMed: 19819942.

30. Zafra C, Abraïdes JG, Turbes J, Berzigotti A, Fernández M et al. (2004) Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126: 749-755. doi:10.1053/gastro.2003.12.007. PubMed: 14988829.

31. Dima A, Marinescu AG, Dima AC (2012) Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med 50: 19-25. PubMed: 22788090.

32. Zamir I Jr, Mattos AA, Mattos AZ, Coral G, Santos D et al. (2010) The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. Arq Gastroenterol 47: 86-92. doi:10.1590/ S0004-28032010000100015. PubMed: 20520981.

33. Tabuchi T, Satoh M, Itoh T, Nakamura M (2012) MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 123: 161-171. doi:10.1042/CS20110563. PubMed: 22384258.

34. Kok SH, Lin LD, Hou KL, Hong CY, Chang CC et al. (2013) Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Arthritis Rheum 65: 639-649. doi:10.1002/art.37807. PubMed: 23291110.

35. Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV et al. (2013) miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 58: 119-125. doi:10.1016/S0168-8278(13)60283-4. PubMed: 22902550.

36. Abraïdes JG, Albillos A, Bafñeres R, Turbes J, González R et al. (2009) Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136: 1651-1658. doi:10.1053/j.gastro.2009.01.043. PubMed: 19208350.

37. Abraïdes JG, Rodríguez-Vilarrubia A, Graupera M, Zafra C, García-Calderó H et al. (2007) Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 46: 1040-1046. doi:10.1016/j.jhep.2007.01.020. PubMed: 17335931.